India Clinical Trials Market Size To Reach $2.22 Billion By 2030

India Clinical Trials Market Growth & Trends

The India clinical trials market size is estimated to reach USD 2.22 billion by 2030, expanding at a CAGR of 8.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The globalization of clinical trials, growing disease variation and prevalence in the country, adoption of new technology in clinical research, and increasing R&D promoting outsourcing are the key factors driving the market.

India is populated with 1.3 billion individuals with varying genetic backgrounds and a large treatment-naïve patient pool for the development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 28 states and 8 union territories present the most diverse disease profile. Apart from this, the cost of carrying out clinical trials in India is nearly 40-70% less when compared to that in Europe or the U.S. Thus, the cost efficiency, along with skill sets and ease of doing business, is anticipated to fuel the market growth.

The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for contract research organizations and outsourcing of trials in order to curb the cost. Furthermore, outsourcing enables the drug companies to focus on their core competencies and aids in improving their productivity, thus facilitating the outsourcing of trials in India. The COVID-19 pandemic has improved the market in the country. Several companies globally are conducting clinical trials for COVID-19 vaccines in India. Moreover, government initiatives promoting clinical trials for COVID-19 therapeutics in the country have promoted market growth.

 Request a free sample copy or view report summary: Indian Clinical Trials Market Report

India Clinical Trials Market Report Highlights

• By phase, the phase I segment is projected to register the fastest growth rate of 9.7% over the forecast period. This can be attributed to the increasing R&D spending by pharmaceutical and biopharmaceutical companies

• The interventional trials segment dominated the market with the largest revenue share in 2024, driven by the widespread adoption of interventional trials recognized for their effectiveness in evaluating the safety and efficacy of new drugs and therapies.

• The oncology segment dominated the market, with the largest revenue share in 2024, and is projected to witness the fastest CAGR over the forecast period

India Clinical Trials Market Segmentation

Grand View Research has segmented the India clinical trials market based on phase, study design, and indication:

India Clinical Trials Phase Outlook (Revenue, USD Million, 2018 - 2030)

• Phase I

• Phase II

• Phase III

• Phase IV

India Clinical Trials Study Design Outlook (Revenue, USD Million, 2018 - 2030)

• Interventional Trials

• Observational Trials

• Expanded Access Trials

India Clinical Trials Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Autoimmune/Inflammation

  • Rheumatoid Arthritis

  • Multiple Sclerosis

  • Osteoarthritis

  • Irritable Bowel Syndrome (IBS)

  • Others

• Pain Management

  • Chronic Pain

  • Acute Pain

• Oncology

  • Blood Cancer

  • Solid Tumors

  • Other

• CNS Conditions

  • Epilepsy

  • Parkinson's Disease (PD)

  • Huntington's Disease

  • Stroke

  • Traumatic Brain Injury (TBI)

  • Amyotrophic Lateral Sclerosis (ALS)

  • Muscle Regeneration

  • Others

• Diabetes

• Obesity

• Cardiovascular

• Others

India Clinical Trials Service Type Outlook (Revenue, USD Million, 2018 - 2030)

• Protocol Designing

• Site Identification

• Patient Recruitment

• Laboratory Services

• Bioanalytical Testing Services

• Clinical Trial Data Management Services

• Others

India Clinical Trials Sponsor Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biopharmaceutical Companies

• Medical Device Companies

• Others

List of Key Players in the India Clinical Trials Market

• IQVIA

• Parexel International (MA) Corporation

• Thermo Fisher Scientific Inc

• Charles River Laboratories

• ICON PLC

• Aurigene Oncology

• Aragen Life Sciences Ltd

• Syneos Health

• SGS Société Générale de Surveillance SA.

• Syngene International Limited.